A strong FDA could pull molecular-diagnostics industry out of a rut

02/18/2014 | Xconomy

Molecular diagnostics have the potential to reduce waste and overtreatment while helping patients, but the field is stuck in a rut, Luke Timmerman writes. "The molecular diagnostics industry needs a tough, science-minded, credible regulator ... who can comb through complex data sets and say with confidence what's real, what's clinically meaningful" and what isn't, he writes. A lack of regulations on companion diagnostics fosters skepticism among payers and investors, Timmerman writes.

View Full Article in:

Xconomy

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Abbott
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA